

Supplementary materials

Content:

Supplementary Table 1

Supplementary Table 2

Supplementary Figure 1

Preprint version

Supplementary Table 1: Distribution of antipsychotic medication types used.

	SCZ (n=56)	BPD (n=31)	All patients (n=87)
<i>SGA</i>			
Olanzapine (N05AH03)	26 (46%)	4 (13%)	31 (35%)
Aripiprazole (N05AX12)	17 (30%)	11 (35%)	28 (32%)
Quetiapine (N05AH04)	5 (9%)	13 (42%)	18 (20%)
Risperidone (N05AX08)	9 (16%)	2 (6%)	11 (13%)
Paliperidone (N05AX13)	8 (14%)	1 (3%)	9 (10%)
Ziprazidone (N05AE04)	3 (5%)	0 (0%)	3 (3%)
Clozapine (N05AH02)	2 (3%)	0 (0%)	2 (2%)
<i>FGA</i>			
Zuclopenthixol (N05AF05)	2 (3%)	0 (0%)	2 (2%)
Haloperidol (N05AD01)	1 (2%)	0 (0%)	1 (1%)
Chlorprothixene (N05AF03)	0 (0%)	1 (3%)	1 (1%)

Anatomical Therapeutic Chemical (ATC) classification codes are provided in the parentheses.

Abbreviations: SCZ: Schizophrenia. BPD: Bipolar disorder. SGA: Second generation antipsychotic agent. FGA: First generation antipsychotic agent.

Supplementary Table 1 – Associations with PANSS total scores and symptom factors.

Region	PANSS total score ¹			Positive factor			Negative factor			Disorganized factor			Excited factor			Depressive factor		
	β	p	p_{corr}	β	p	p_{corr}	β	p	p_{corr}	β	p	p_{corr}	β	p	p_{corr}	β	p	p_{corr}
<i>Left hemisphere</i>																		
Superior frontal	.04	.68	.96	.10	.32	.94	.01	.91	.98	.08	.36	.94	.14	.09	.76	-.07	.37	.94
Pars opercularis	.03	.76	.96	.05	.51	.96	-.03	.72	.96	.10	.24	.83	.14	.07	.76	-.03	.70	.96
Caudal anterior cingulate	.04	.68	.96	.07	.45	.96	.02	.81	.97	.05	.55	.96	.13	.10	.76	-.07	.41	.94
Precuneus	.05	.61	.96	.14	.14	.76	-.04	.67	.96	.05	.55	.96	.14	.09	.76	-.04	.65	.96
Insula	.02	.81	.97	.12	.20	.76	-.03	.79	.97	.17	.04	.76	.11	.17	.76	-.11	.18	.76
Middle temporal	.07	.45	.96	.10	.32	.94	.00	.99	.99	.14	.10	.76	.16	.05	.76	-.01	.89	.98
Precentral	.00	.99	.99	.05	.63	.96	-.01	.91	.98	.07	.42	.94	.08	.30	.94	-.03	.70	.96
Superior temporal	.05	.47	.96	.09	.32	.94	-.04	.68	.96	.12	.17	.76	.11	.17	.76	-.03	.70	.96
Fusiform gyrus	-.03	.76	.96	.09	.35	.94	-.01	.89	.98	-.03	.71	.96	.07	.40	.94	-.05	.55	.96
Supramarginal	-.05	.62	.96	.03	.73	.96	-.12	.20	.76	.08	.36	.94	.11	.20	.76	-.03	.72	.96
Lateral occipital	.05	.59	.96	.14	.14	.76	-.04	.64	.96	.04	.67	.96	.13	.10	.76	.02	.78	.96
Banks of the superior temporal sulcus	-.01	.92	.98	.10	.31	.94	-.04	.68	.96	.03	.76	.96	.13	.11	.76	-.08	.31	.94
<i>Right hemisphere</i>																		
Rostral middle frontal	.09	.36	.94	.17	.08	.76	-.06	.55	.96	.13	.13	.76	.21	.01	.52	-.01	.94	.98
Superior parietal	.04	.65	.96	.03	.78	.96	-.02	.85	.98	.08	.38	.94	.10	.22	.79	.04	.66	.96
Insula (1)	.17	.08	.76	.21	.03	.75	.03	.78	.96	.23	.009	.52	.20	.01	.52	-.01	.91	.98
Superior temporal	.08	.39	.94	.13	.17	.76	.02	.85	.98	.11	.20	.76	.12	.13	.76	-.01	.86	.98
Superior frontal (1)	.05	.60	.96	.05	.57	.96	-.05	.56	.96	.16	.06	.76	.11	.17	.76	.07	.40	.94
Precuneus (1)	.06	.55	.96	.09	.35	.94	.01	.92	.98	.05	.55	.96	.13	.12	.76	-.09	.93	.98
Precuneus (2)	-.02	.86	.98	.05	.63	.96	.06	.50	.96	.05	.58	.96	.07	.42	.94	.00	.97	.99
Insula (2)	.12	.20	.76	.13	.17	.76	.04	.65	.96	.16	.07	.76	.18	.02	.75	-.04	.62	.96
Superior frontal (2)	.03	.74	.96	-.02	.85	.98	.01	.88	.98	.03	.71	.96	.07	.35	.94	.10	.22	.8
Postcentral	-.07	.51	.96	-.09	.33	.94	-.02	.83	.98	.00	.99	.99	.00	.99	.99	.00	.99	.99

Linear regression models (n=155) adjusted for age, sex, and diagnosis.

¹For PANSS total score and negative symptom factor n=154 due to missing data in one participant.

Supplementary Figure 1 – Age slopes in all significant clusters



Scatterplots showing the associations with age for each significant cluster from the surface analyses for SCZ (red line), BPD (blue line) and CTR (green line). The x-axes represent age, and the y-axes represent mean T1w/T2w-ratio values within the cluster.